Skip to main content

Education/ACR/EULAR

      RT @EBRheum: MAINRITSAN3 RCT, RTX v PLBO in AAV

      28mo relapse free survival ⬇️ RTX (96% vs 74%, NNT~4), majr (100% v
      4 years 6 months ago
      MAINRITSAN3 RCT, RTX v PLBO in AAV 28mo relapse free survival ⬇️ RTX (96% vs 74%, NNT~4), majr (100% vs 87%, NNT~8) 1. Selected grp (all pts from MAINRITSAN2) 2. All pts had GC q3mos - IRL benefit could be bigger? Strong data for RTX >2yrs in AAV PDF: https://t.co/Mbrq7bFHk0 https://t.co/auKJ3QPKr0
      Yet another NEGATIVE Trial in Hand OA. Add Hand OA to the list that Includes Scleroderma, Sjogrens and CRPS as untreatab
      4 years 6 months ago
      Yet another NEGATIVE Trial in Hand OA. Add Hand OA to the list that Includes Scleroderma, Sjogrens and CRPS as untreatable diseases with large unmet needs! https://t.co/cMMqmeo19N
      RT @philipcrobinson: Anti-CD74 IgA antibodies are most sensitive and specific to identify young male axSpA patients, dat
      4 years 6 months ago
      Anti-CD74 IgA antibodies are most sensitive and specific to identify young male axSpA patients, data from @XBaraliakos and others: Abstract FRI0312 #EULAR2020 @RheumNow https://t.co/yrevk8Wsiw https://t.co/kzcje2rRNa
      RT @philipcrobinson: ASAS modification of the Berlin algorithm and the duet algorithm for diagnosing axSpA : results fro
      4 years 6 months ago
      ASAS modification of the Berlin algorithm and the duet algorithm for diagnosing axSpA : results from the screening in axSpA for psoriasis, iritis, and colitis cohort: Abstract FRI0298 #EULAR2020 @RheumNow https://t.co/BkG7c2riRb https://t.co/f63MsxWmd3
      RT @philipcrobinson: Drug retention rates & treatment outcomes in 1,860 axSpA patients Rx with secukinumab in routin
      4 years 6 months ago
      Drug retention rates & treatment outcomes in 1,860 axSpA patients Rx with secukinumab in routine clinical practice in 13 European countries in the EuroSpA research collaboration network -> registry data drug retention rates THU0398 @RheumNow #EULAR2020 https://t.co/x3Y4tMetij https://t.co/DkUyIfyWwS
      RT @philipcrobinson: The Relative Diagnostic Utility of inflamm back pain criteria in inception cohort with PsO, Iritis,
      4 years 6 months ago
      The Relative Diagnostic Utility of inflamm back pain criteria in inception cohort with PsO, Iritis, & Colitis Presenting With Undiagnosed Back Pain: All IBP criteria have poor diagnostic utility for dx of axSpA, esp in PsO Abs SAT0378 #EULAR2020 @RheumNow https://t.co/Y7sbtJtm3U https://t.co/P9q7uJozZ9
      RT @philipcrobinson: Filgotinib was associated with significant reduction in SIJ erosion scores in axSpA: imaging data f
      4 years 6 months ago
      Filgotinib was associated with significant reduction in SIJ erosion scores in axSpA: imaging data from the double-blind, randomized Tortuga trial #EULAR2020 @rheumnow THU0377 https://t.co/1b18Uyvo5j https://t.co/zBXCwGc0Q7
      RT @philipcrobinson: Integrated safety analysis of filgotinib treatment for RA from 7 clinical trials: 4,057 patients, V
      4 years 6 months ago
      Integrated safety analysis of filgotinib treatment for RA from 7 clinical trials: 4,057 patients, VTE risk looks very reassuring #EULAR2020 @RheumNow https://t.co/Ld2tpu7UT5 https://t.co/sZqadeUTh8
      RT @philipcrobinson: Great talk on inflammasomes at #EULAR2020 by @dave_boucher: 4th June, 1:15pm, Ansell: Inflammasome
      4 years 6 months ago
      Great talk on inflammasomes at #EULAR2020 by @dave_boucher: 4th June, 1:15pm, Ansell: Inflammasome activation in rheumatic diseases: mechanisms and perspectives for therapy @RheumNow https://t.co/HTWVxt4FMz
      RT @philipcrobinson: Replacing radiographic sacroiliitis with MRI structural damage doesn't change the classifciation of
      4 years 6 months ago
      Replacing radiographic sacroiliitis with MRI structural damage doesn't change the classifciation of axSpA signifciantly @RheumNow #EULAR2020 Abstract SAT0384 https://t.co/MTTf4fHjYT
      ×